A1 Refereed original research article in a scientific journal
Pretreatment with Prasugrel in Non-ST-Segment Elevation Acute Coronary Syndromes
Authors: Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, ten Berg JM, Miller DL, Costigan TM, Goedicke J, Silvain J, Angioli P, Legutko J, Niethammer M, Motovska Z, Jakubowski JA, Cayla G, Visconti LO, Vicaut E, Widimsky P, ACCOAST Investigators
Publisher: MASSACHUSETTS MEDICAL SOC
Publication year: 2013
Journal: New England Journal of Medicine
Journal name in source: NEW ENGLAND JOURNAL OF MEDICINE
Journal acronym: NEW ENGL J MED
Number in series: 11
Volume: 369
Issue: 11
First page : 999
Last page: 1010
Number of pages: 12
ISSN: 0028-4793
DOI: https://doi.org/10.1056/NEJMoa1308075
Abstract
ConclusionsAmong patients with NSTE acute coronary syndromes who were scheduled to undergo catheterization, pretreatment with prasugrel did not reduce the rate of major ischemic events up to 30 days but increased the rate of major bleeding complications. (Funded by Daiichi Sankyo and Eli Lilly; ACCOAST ClinicalTrials.gov number, NCT01015287.)
ConclusionsAmong patients with NSTE acute coronary syndromes who were scheduled to undergo catheterization, pretreatment with prasugrel did not reduce the rate of major ischemic events up to 30 days but increased the rate of major bleeding complications. (Funded by Daiichi Sankyo and Eli Lilly; ACCOAST ClinicalTrials.gov number, NCT01015287.)
UTU Research Portal